Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study
Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...
Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...
Leqembi, Alzheimer’s Drug by Eisai and Biogen, Now Covered by Qihuibao Insurance in China
Leqembi (lecanemab), an Alzheimer’s disease treatment co-developed by Eisai Co., Ltd (TYO: 4523) and Biogen...
Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China
Bayer AG (ETR: BAYN), a leading German multinational pharmaceutical and life sciences company, has expanded...
Changchun High & New Technology Industries Receives FDA Tacit Approval for GenSci122 Clinical Study
Changchun High & New Technology Industries (Group) Inc. (SHE: 000661), a leading biopharmaceutical company, has...
Jiangsu Hengrui’s HR19042 Earns Breakthrough Designation for Autoimmune Hepatitis Treatment in China
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced...
Eli Lilly’s Mirikizumab Shows Statistically Significant Improvement in Crohn’s Disease VIVID-1 Study
Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the U.S., has published...
Humanwell Healthcare Secures NMPA Approval for Clinical Trial of HW211026 to Treat Actinic Keratosis
Humanwell Healthcare (Group) Co., Ltd (SHA: 600079), a China-based pharmaceutical company, has announced that it...
Thermo Fisher Faces FDA Scrutiny Over Syringe Air Bubble Protocols at North Carolina Plant
Thermo Fisher Scientific’s (NYSE: TMO) Greenville, North Carolina, facility has come under scrutiny after a...
United Laboratories’ TUL12101 Eye Drops Enter Phase IIa Clinical Trial for Dry Eye Syndrome
United Laboratories International Holdings Ltd (HKG: 3933), a Hong Kong-based pharmaceutical company, has announced the...
3D Medicines’ Envafolimab Earns NMPA Breakthrough Designation for TMB-H Solid Tumors
3D Medicines (HKG: 1244), a biopharmaceutical company based in China, has announced that its envafolimab...
Roche’s Vabysmo Receives NMPA Approval for Macular Edema Treatments in China
Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced the receipt of another marketing approval...
Intas Pharmaceuticals Receives FDA Approval for Biosimilar Stelara, Expanding Treatment Options for Autoimmune Diseases
Intas Pharmaceuticals Ltd, an Indian pharmaceutical company and partner of China’s Shanghai Henlius Biotech Inc....
Beijing Aims to Build a Leading Cell and Gene Therapy Hub by 2026 with New Action Plan
The Beijing Municipal Science & Technology Commission, in conjunction with the Administrative Commission of Zhongguancun...
RemeGen’s Disitamab Vedotin Receives Priority Review for New Indication in Breast Cancer by China’s NMPA
RemeGen Ltd (HKG: 9995), a biopharmaceutical company based in China, has announced that the Center...
Lundbeck Secures Rights to Bexicaserin with Acquisition of Longboard Pharmaceuticals
Lundbeck A/S (VIE: LUNA), a Danish pharmaceutical company, has announced its intention to acquire U.S.-based...
Stemirna Therapeutics, Once a Leading mRNA Developer in China, Enters Bankruptcy Proceedings
Stemirna Therapeutics Co., Ltd, a one-time leading mRNA developer in China, has officially commenced bankruptcy...
Novo Nordisk Expands Legal Campaign to 50 Cases Against Semaglutide Compounders
Novo Nordisk (NYSE: NVO) has escalated its legal battles in the healthcare sector by filing...
AstraZeneca and Daiichi Sankyo’s Enhertu Receives Fourth Indication Approval in China
AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568)’s co-developed antibody drug conjugate (ADC), Enhertu (trastuzumab...
BMS’s Dual Immunotherapy Achieves Global First Approval for MSI-H/dMMR CRC in China
On October 14, 2024, Bristol-Myers Squibb (BMS, NYSE: BMY) announced that the National Medical Products...